Business Wire

TSURUMI-BREWING

30.11.2015 15:01:49 CET | Business Wire | Press release

Share
Sales to Begin of Tsurumi Brewing's SUSHI SAKE—A Sake Expressly for Sushi, Japan's Culinary Gift to the World

Founded in 1873, Tsurumi Shuzou Co., Ltd. (hereinafter, Tsurumi Brewing ) have developed SUSHI SAKE Kamitsuru Junmai Daiginjo (junmai means it is made with only rice products and no added alcohol, and daiginjo refers to the fact that the rice has been milled to fifty percent or less of its weight during the process), based on the concept of having a Japanese sake to go with sushi, in conjunction with the boom we are currently seeing in sake popularity outside of Japan. Sales have begun in November of 2015.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151130005179/en/

Product info: http://www.tsurumi-jp.com/sushi_sake/en

Priced at ¥12,000 per bottle, SUSHI SAKE Kamitsuru Junmai Daiginjo, a Sake for Sushi

Tsurumi Brewing, a company that produces and sells sake, began sales of SUSHI SAKE Kamitsuru Junmai Daiginjo in November, working from the notion that sake could serve to improve the wonderful taste of sushi, beloved world-wide, and representative of Japan’s food culture.

We designed SUSHI SAKE to hold back the raw odors unique to the fish used in sushi on your palette while paying particular attention to the balance for the earthier, umami flavors. By offering a crisp finishing tone, you will find it goes very well with sushi by preparing you for the next bite.

Developed by a Venerable Japanese Sake Brewer

Development of SUSHI SAKE occurred at Tsurumi Brewing, an esteemed, established sake brewery in Aichi Prefecture. Tsurumi Brewing began its history in 1873 when founder Teizo Tsurumi, who had been working with dyed goods, opened a sake brewery.

We maintain the traditional methods of production that have been handed down in the Tsushima area, striving to protect the merits of production by hand in the process. At the same time, we are also working to harmonize these methods with more modern systems of quality control and ingenuity, as we strive to create even better sake, and drawing out the depths of flavor inherent in the rice to impart a truly rich taste.

Completed After Trial and Error Under the Tutelage of the Master of a Long-established Restaurant, Founded in 1934

When it came to put the finishing touches on SUSHI SAKE, we turned to the advice of a respected, long-established restaurant, having many fans across Japan. This, we knew, would be critical in our process for the sixth generation of the Tsurumi family who currently operates the company that was founded in 1873.

Using only Yamadanishiki rice, we mill it down to forty percent of its weight. We draw water from an underground source of the Kiso River. Fermentation of the sake occurs at the optimal low temperatures found during the peak of winter, and it is the skill and dedication of the chief brewer, applied slowly over time, that results in the highest quality sake. You will enjoy a subtly rich taste.

Plans to Expand Sales from Shanghai and Hong Kong to Paris and New York

At present, SUSHI SAKE is available at the most established restaurants and department stores in Japan, but starting in December, there will be tastings planned, along with Japanese food, at restaurants in Italy. Moving forward, we plan to expand exports to Shanghai, Hong Kong, Paris, and New York. We will also be increasing availability at restaurants within Japan, as well as sales at department stores and online. Other varieties of SUSHI SAKE in addition to Junmai Daiginjo will be available for sale as well, including Daiginjo, Junmai Ginjo, Ginjo, and Junmai (ginjo refers to the fact that the rice has been milled to 60% of its weight or less).

 

Product Facts

Name  

:

  SUSHI SAKE Kamitsuru Junmai Daiginjo
Price

:

¥12,000 (pre-tax)
Volume

:

1,800 ml
Ingredients

:

Rice, rice malt
Percent alcohol

:

15.5%
Rice used

:

100% Yamadanishiki
Milling degree

:

40%
 

Corporate Overview

Name  

:

  Tsurumi Shuzou Co., Ltd.
Address

:

46 Asahi, Hyaku-cho, Tsushima City, Aichi Prefecture
Representative

:

Masahito Tsurumi
Capitalization

:

¥10 million
Established

:

1873
Incorporation

:

December 1949
Business

:

Production, wholesaling, and retailing of sake, mirin, liqueurs, shochu products, fruit wines, fortified wines, miscellaneous liquors, spirits, beer, and vinegar
Website

:

http://www.tsurumi-jp.com/sushi_sake/en

Contact:

TSURUMI SHUZOU Co., Ltd.
Masahito Tsurumi, +81-567-31-1141
tsurumi@tsurumi-jp.com
Fax: +81-567-32-0586

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye